Literature DB >> 30807339

Management of Chronic Hypertension Following Intracerebral Hemorrhage.

Edward T Van Matre1, Aaron M Cook, Samarth P Shah, Alexandria C Rydz, Keaton S Smetana.   

Abstract

Acute blood pressure control after a cerebrovascular event is integral in the immediate care of these patients to preserve perfusion to ischemic areas and prevent intracerebral bleeding. The majority of patients with ischemic stroke or intracerebral hemorrhage (ICH) present with preexisting hypertension and therefore require a treatment plan after the acute phase. The presence of chronic hypertension after ICH has often been discussed as a modifiable risk factor for recurrent events. Clinical evidence is relatively lacking for clinicians to understand the extent of blood pressure lowering and the optimal agents to use in this setting. Limited data exist describing the long-term management of hypertension in patients after cerebrovascular events. This review provides nurses with a summary of the available literature on long-term blood pressure management to minimize the risk of secondary ICH and ischemic stroke. It focuses on oral antihypertensive medications available in the United States that may be utilized to manage chronic hypertension immediately after the postacute phase of care to lower blood pressure and to improve long-term outcomes.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30807339     DOI: 10.1097/CNQ.0000000000000248

Source DB:  PubMed          Journal:  Crit Care Nurs Q        ISSN: 0887-9303


  2 in total

1.  Hypertension Among Hemorrhagic Stroke Patients in Northeast China: A Population-Based Study 2017-2019.

Authors:  Haoran Dong; Shuang Liu; Li Jing; Mengyuan Tian; Jinglun Sun; Yanmin Pang; Liying Xing; Yingying Xu
Journal:  Med Sci Monit       Date:  2020-12-30

2.  Observation on the Effect of Solution-Focused Approach Combined with Family Involvement in WeChat Platform Management on Inpatients with Intracerebral Hemorrhage.

Authors:  Yu Song
Journal:  J Healthc Eng       Date:  2022-03-19       Impact factor: 2.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.